Search research articles
Contact Us
Filters
Showing results (41-50 of 740) with videos related to
Page
of 74
Sort By:
The Lancet. Haematology
|
October 7, 2018
Thalidomide for myeloma: still here?
Meletios A Dimopoulos, Efstathios Kastritis
Nature Reviews. Clinical Oncology
|
November 28, 2009
Hematology: first-line bortezomib benefits patients with multiple myeloma
Meletios A Dimopoulos, Evangelos Terpos
The American Journal of Medicine
|
October 7, 2004
Adverse effects of thalidomide administration in patients with neoplastic diseases
Meletios A Dimopoulos, Vagelis Eleutherakis-Papaiakovou
The Lancet. Oncology
|
January 6, 2018
Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply
Meletios A Dimopoulos, Amy S Kimball
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2023
Reply to S. Al Hadidi et al
Meletios A Dimopoulos, Jesús San-Miguel
Seminars in Hematology
|
April 25, 2009
Treatment of relapsed/refractory multiple myeloma
Efstathios Kastritis, Antonio Palumbo, Meletios A Dimopoulos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2003
Treatment of plasma cell dyscrasias with thalidomide and its derivatives
Meletios A Dimopoulos, Athanasios Anagnostopoulos, Donna Weber
The New England Journal of Medicine
|
November 15, 2018
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia
Meletios A Dimopoulos, Zeena Salman, Christian Buske
Advances in Chronic Kidney Disease
|
August 28, 2012
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective
Esftathios Kastritis, Meletios A Dimopoulos, Joan Bladé
Expert Opinion on Pharmacotherapy
|
May 28, 2013
Current treatments for renal failure due to multiple myeloma
Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Page
of 74
Search research articles
Search
Showing results (41-50 of 740) with videos related to
Sort By:
Page
of 74
The Lancet. Haematology
|
October 7, 2018
Thalidomide for myeloma: still here?
Meletios A Dimopoulos, Efstathios Kastritis
Nature Reviews. Clinical Oncology
|
November 28, 2009
Hematology: first-line bortezomib benefits patients with multiple myeloma
Meletios A Dimopoulos, Evangelos Terpos
The American Journal of Medicine
|
October 7, 2004
Adverse effects of thalidomide administration in patients with neoplastic diseases
Meletios A Dimopoulos, Vagelis Eleutherakis-Papaiakovou
The Lancet. Oncology
|
January 6, 2018
Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply
Meletios A Dimopoulos, Amy S Kimball
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2023
Reply to S. Al Hadidi et al
Meletios A Dimopoulos, Jesús San-Miguel
Seminars in Hematology
|
April 25, 2009
Treatment of relapsed/refractory multiple myeloma
Efstathios Kastritis, Antonio Palumbo, Meletios A Dimopoulos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2003
Treatment of plasma cell dyscrasias with thalidomide and its derivatives
Meletios A Dimopoulos, Athanasios Anagnostopoulos, Donna Weber
The New England Journal of Medicine
|
November 15, 2018
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia
Meletios A Dimopoulos, Zeena Salman, Christian Buske
Advances in Chronic Kidney Disease
|
August 28, 2012
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective
Esftathios Kastritis, Meletios A Dimopoulos, Joan Bladé
Expert Opinion on Pharmacotherapy
|
May 28, 2013
Current treatments for renal failure due to multiple myeloma
Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos
Page
of 74